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Edited by Robert BaroukiAbstract PCIF1 is a TRAF and POZ domain containing
nuclear factor that interacts with and inhibits transactivation
of pancreatic homeodomain transcription factor PDX-1. Here,
we demonstrate interaction of endogenous PDX-1 and PCIF1
in MIN6 insulinoma cells. Within PCIF1, the TRAF and POZ
domains are both required for physical and functional interaction
with the C-terminus of PDX-1, whereas the C-terminal domain
of PCIF1 directs its nuclear localization. A human PDX-1 muta-
tion associated with diabetes, E224K, disrupts the ability of
PCIF1 to inhibit PDX-1 transactivation, suggesting that the
interaction between PDX-1 and PCIF1 is required for normal
glucose homeostasis. Inhibition of transactivation occurs by a
mechanism distinct from the classical role of POZ domains to
recruit co-repressors and histone deacetylases. Understanding
the functional roles of PCIF1 domains may have application to
therapeutic b-cell replacement strategies involving PDX-1 for
the treatment of diabetes.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Insulin1. Introduction
PDX-1 (pancreas and duodenum homeobox-1) is aHox type
homeodomain-transcription factor that is pivotally positioned
in the transcriptional hierarchy governing pancreatic b-cell
development. PDX-1 has two critical roles, ﬁrst in the early
development of both the endocrine and exocrine pancreas,
and then in the later diﬀerentiation of the b-cell (reviewed in
[1,2]). Mice and humans deﬁcient for Pdx1 have pancreatic
agenesis. Heterozygous null Pdx1 mutation leads to the devel-
opment of an initially normal morphological mass of b-cells
but impaired b-cell function and impaired cell survival leading
to abnormal glucose tolerance in mice and early-(MODY4)
and late-onset forms of type 2 diabetes in humans.Abbreviations: PDX-1, pancreas and duodenum homeobox-1; MODY,
maturity onset diabetes of youth; PCIF1, PDX-1 C-terminus interact-
ing factor; MIN6, mouse insulinoma cell line 6; TRAF, TNF-receptor
associated factor domain; POZ, poxvirus and zinc ﬁnger domain; BTB,
broad-complex, tramtrack, and bric-a-brac domain; HDAC, histone
deacetylase; PCR, polymerase chain reaction
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doi:10.1016/j.febslet.2006.11.021In contrast to the N-terminal transactivation domain and
the DNA binding homeodomain, the role of the C-terminus
of PDX-1 is poorly understood. Human mutations in the
regions are associated with adult onset type 2 diabetes and
MODY, emphasizing its functional importance in vivo [3–5].
Some data support an inhibitory role [6–9], yet other data indi-
cate that the C-terminus is required for full transactivation
[3,4]. Recently, the concept that the insulin gene is actively re-
pressed under low glucose conditions has been put forth [10],
mediated by recruitment of histone deacetylases (HDAC) 1
and 2 to PDX-1 amino acids 79–284, suggestive of a context-
dependent repressive role of either the homeodomain or the
C-terminus [11].
We previously identiﬁed PCIF1 (PDX C-terminus Interact-
ing Factor-1) as a partner for PDX-1 in a yeast two-hybrid
screen [12]. PCIF1 encodes a 374 amino acid protein with an
N-terminal TNF receptor associated factor (TRAF) domain
and a typical poxvirus and zinc ﬁnger (POZ) domain. The
physical interaction between PCIF1 and PDX-1 was conﬁrmed
in vitro by GST interaction assay and in vivo by co-immuno-
precipitation of over-expressed proteins. Functionally, PCIF1
inhibits PDX-1 transactivation of target gene promoters in a
speciﬁc and dose-dependent manner that requires an intact
PDX-1 C-terminus. PCIF1 mRNA is enriched in adult pan-
creas, and PCIF1 protein is expressed in adult pancreatic insu-
lin-producing b-cells. The co-expression of PCIF1 with PDX-1
in b-cells and its ability to inhibit PDX-1 transactivation sug-
gest that PCIF1 modulation of PDX-1 function may regulate
b-cell diﬀerentiation.2. Materials and methods
2.1. Constructs
Expression vectors were full length mouse PDX-1, mouse PDX-1(1-
210), pGBKT7-PDX-1(144–283) and GST-PDX-1(206–283) [12], rat
PDX-1 [13], human PDX-1 [14], zebraﬁsh PDX-1 [15], Flag-PCIF1
[12], Gal-4 PDX-1 [6], Gal-4 BCL6 POZ and Gal-4 PLZF POZ [16],
human PDX-1 wild-type and E224K [3] and GST-TRAF and GST-
POZ [17]. Reporters were the PDX-1-responsive somatostatin pro-
moter reporter (TAAT)5-65 SMS-CAT [13] and the Gal4 responsive
reporters G51bCAT [12] and Gal4SV40Luc. Flag-tagged mutants of
PCIF1 and Gal4-PCIF1 constructs were created by polymerase chain
reaction (PCR). Primers and details of cloning strategies are available
upon request. All constructs were conﬁrmed by sequencing.2.2. Immunoprecipitations and Western blot analysis
Mouse insulinoma cell line 6 (MIN6) cells were lysed in 150 mM
NaCl, 40 mM Tris–HCl, pH 7.6, 10% glycerol and 0.3% NP-40 and
immunoprecipitations were carried out as described [12]. Primaryblished by Elsevier B.V. All rights reserved.
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(Santa Cruz #sc-11417); HDAC2 (Santa Cruz #sc-7899); SMRT
(mouse, gift from Mitch Lazar) and SMRT (ABR, # PA1-842). PCIF1
and PDX-1 antisera were previously described [12,14].
2.3. Transfections
HeLa cells were transfected with expression and reporter vectors and
an internal control cmv-b galactosidase expression vector. Chloram-
phenicol acetyl transferase, luciferase and b-galactosidase activities
were measured as described [12].
2.4. GST interaction assays
Bacterially expressed GST fusion proteins were incubated with
in vitro-transcribed and -translated 35S-labelled full length PDX1,
PDX1(1–210), PDX1(D210–238), PDX1(144–283) [12]. After washing,
proteins bound to glutathione beads were analyzed by SDS–PAGE.
2.5. Immunoﬂuorescence
Transfected cells were stained with a Flag monoclonal antibody as
described [12].3. Results
3.1. In vivo association of endogenous PDX-1 and PCIF1
PDX-1 and PCIF1 are associated when over-expressed in
HeLa cells [12]. To rule out artifactual association due to
high-level over-expression, we determined whether endogenous
PDX-1 and PCIF1 associate in vivo. Using extracts prepared
from MIN6 insulinoma cells that express both PDX-1 and
PCIF1, immunoprecipitation with a-PDX1 resulted in the
co-immunoprecipitation of PCIF1, whereas control immuno-
globulin did not (Fig. 1), indicating a speciﬁc interaction be-
tween endogenous PDX-1 and PCIF1.
3.2. An evolutionarily conserved motif in the PDX-1 C-terminus
mediates the physical and functional interaction with PCIF1
We previously localized the functional ability of PCIF1 to
inhibit Gal4-PDX1 fusion protein transactivation to amino
acids (AA) 210–238 of the PDX-1 C-terminus. Here we show
that the functional interaction of PCIF1 with PDX-1 is evolu-
tionarily conserved. Transactivation by mouse, rat, human and
zebraﬁsh PDX-1 is similarly inhibited by mouse PCIF1
(Fig. 2A), indicating that PCIF1 interacts with a conserved
motif in PDX-1. Comparison of the C-terminus from multiple
species reveals a highly conserved 14 AA motif (Fig. 2B). In
agreement with our previous ﬁndings in a series of Gal4
PDX-1 truncations, internal deletion of AA 210–238 from fullFig. 1. Interaction of endogenous PDX-1 and PCIF1 in MIN6
insulinoma cells. Cell extracts were immunoprecipitated with
a-PDX1 and immunoblotted with a-PDX1 and a-PCIF1. Lane 1,
2% of input extract; lane 2, pre-immune IP; lane 3, a-PDX-1 IP.length PDX-1, including the conserved motif, abrogated the
ability of PCIF1 to inhibit PDX-1 (Fig. 2C). This is due to
the requirement of AA 210–238 for co-immunoprecipitation
of PDX-1 and PCIF1 (Fig. 2D), indicating that these residues
are essential for both the physical and functional interaction of
PDX-1 and PCIF1.3.3. Diabetogenic E224K PDX-1 mutation impairs the
functional eﬀect of PCIF1
A recent genetic report described a novel diabetes-associated
mutation, E224K, in the PDX-1 C-terminus in two diabetic
subjects from Trinidad [3]. Within one large family the muta-
tion co-segregated with early onset diabetes, suggesting a
MODY4 form of diabetes. The E224K mutation results in
the replacement of a negative charge with a positively charged
side chain, and it occurs within the conserved motif that medi-
ates physical and functional interaction with PCIF1 (Fig. 2B).
Therefore, we examined the ability of PCIF1 to inhibit the
E224K variant in transient transfection assays. PCIF1 does
not inhibit transactivation of the PDX-1 E224K mutant pro-
tein, in agreement with the above data indicating the critical
importance of this motif and in contrast to the eﬀect of PCIF1
on wild-type human PDX-1 (Fig. 3).3.4. Both POZ and TRAF domains mediate the physical
interaction with PDX-1
To map the critical motifs in PCIF1 that mediate interaction
with PDX-1 we created deletion mutants of PCIF1 in which
the TRAF, POZ or C-terminal domains were removed
(Fig. 4A). GST interaction assays demonstrated the interaction
of GST-PDX1 (206–283) with full length PCIF1 as previously
reported (Fig. 4B) [12]. PCIF1 (1–161)(m1) and (1–298)(m4)
showed the strongest signal, suggesting that the N-terminus
containing the TRAF domain mediates the physical interac-
tion with PDX-1. A weak interaction with PCIF1 (D162–
298)(m3) was also observed, consistent with a TRAF
domain-mediated interaction.
The requirement for the TRAF domain was directly tested in
GST interaction assays utilizing recombinant GST-TRAF and
GST-POZ fusion proteins (Fig. 4C). A strong speciﬁc interac-
tion between GST-TRAF and full length PDX-1 was ob-
served. A weaker but speciﬁc interaction with GST-POZ was
also observed. Similarly, both GST-TRAF and GST-POZ spe-
ciﬁcally pulled down PDX-1 (144–283), encoding the homeo-
domain and C-terminus of PDX-1. The interaction with both
GST-TRAF and GST-POZ was abrogated with the truncation
of the PDX-1 C-terminus at amino acid 210 [PDX1(1–210)].
Thus, both the TRAF and POZ domains mediate physical
interaction of PCIF1 with the C-terminus of PDX-1. Of note,
internal deletion of residues 210–238 [PDX1(D210–238)] abro-
gated interaction with the TRAF domain but not the POZ do-
main, indicating that the POZ domain has additional contacts
with the PDX-1 C-terminus outside of the conserved motif
required for functional inhibition by PCIF1.3.5. Critical roles of TRAF, POZ and C-terminal domains in
PCIF1 inhibition of PDX-1 transactivation
The domain requirements for PCIF1 inhibition of PDX-1
were assessed in over-expression reporter assays (Fig. 4D).
Deletion of the TRAF, POZ or C-terminal domains individu-
ally each abrogated the inhibitory eﬀect of PCIF1, indicating
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Fig. 2. Evolutionarily conserved PDX-1 amino acids 210–238 are critically required for physical and functional interaction with PCIF1. (A)
Evolutionary conservation of PCIF1 function. Transactivation tested in transient transfection assays in HeLa cells using the SMS(TAAT1)5CAT
reporter. The activity of each PDX ortholog (mouse, rat, human and zebraﬁsh) in the absence of PCIF1 was set to 100% (black boxes) for
comparison to activity in the presence of PCIF1 (shaded boxes). (B) Evolutionary comparison of the amino acid sequence of the PDX-1 proximal C-
terminus. The entire coding sequences of mouse, rat, human, hamster, frog and zebraﬁsh PDX-1 are indicated in compressed form, with residues
identical to the mouse sequence shaded in black. Regions of high identity include the transactivation domain (TAD), the Pbx interaction motif
(PIM), the homeodomain and a 14 amino acid peptide in the C-terminus, the proposed PCIF1-Interaction Module (PCIF1-IM; in blue). The PCIF1-
IM sequence is expanded below and the location of the human diabetes mutation, E224K, is indicated by an asterisk (*). (C) and (D) Internal
deletion of evolutionarily conserved AA 210–238 abrogates (C) the ability of PCIF1 to inhibit PDX-1 transactivation and (D) the PCIF1 interaction
with PDX-1. (C) The activity of PDX-1D210–238 was compared to PDX-1 in the absence (black boxes; empty vector) and presence (shaded boxes) of
co-transfected PCIF1 expression vector. Transfections were carried out in HeLa cells, using the SMS(TAAT1)5 CAT reporter. (D) Empty vector,
PDX-1 and PDX-1D210–238 were co-transfected with empty vector or PCIF1 into HeLa cells and subjected to immunoprecipitation with a-PDX-1
antiserum (lower panel). PCIF1 was detected in association with full length PDX-1 but not PDX-1D210–238 (upper panel).
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Fig. 3. Diabetogenic E224K mutation in human PDX-1 disrupts the
ability of PCIF1 to inhibit PDX-1 transactivation. Transactivation was
tested in transient transfection assays in HeLa cells using the
SMS(TAAT1)5CAT reporter. The activity of wild-type (WT) and
E224K mutated human PDX-1 (E224K) was assessed in the presence
and absence of PCIF1. Activity of wild-type human PDX-1 in the
absence of PCIF1 was set to 100%. *P < 0.001. NS, not signiﬁcant. EV,
empty vector.
Fig. 4. Critical role of the BTB/POZ and TRAF domains in the
physical and functional interaction of PCIF1 with PDX-1. (A) Flag
tagged PCIF1 deletion mutants are depicted in schematic form. (B)
GST-PDX-1 206–283 interaction assays with 35S-labelled in vitro
transcribed and translated PCIF1 and PCIF1 deletion mutants. Lane 1
GST only; lanes 2–7 GST-PDX-1 206-283; lanes 1–3 PCIF1 (wt); lane
4 NT (m1); lane 5 PC (m2); lane 6 DPOZ (m3); lane 7 DC (m4). (C)
GST TRAF and GST POZ interaction assays with 35S-labelled in vitro
transcribed and translated PDX-1 and PDX-1 mutants 1–210, D210–
238 and 144–283. Western blots shown are representative of three
independent experiments. (D) Upper panel, Full-length PCIF1 and
PCIF1 deletion mutants tested in transient transfection assays for the
ability to inhibit PDX-1 transactivation of the SMS(TAAT1)5CAT
reporter. Transactivation of PDX-1 in the absence of PCIF1 is set to
100%. Lower panel, Western blot demonstrating expression of PCIF1
and PCIF1 deletion mutants in transfected HeLa cells.
6704 A. Liu et al. / FEBS Letters 580 (2006) 6701–6706the requirements for all three domains for the ability of PCIF1
to inhibit PDX-1 transactivation.
3.6. The PCIF1 POZ domain is not an autonomous repression
domain
The most well characterized POZ domain transcription fac-
tors are transcriptional repressors in which the POZ domain
mediates direct interactions with co-repressors and HDACs
[18,19]. To determine whether the PCIF1 POZ domain medi-
ates inhibition of PDX-1 by a similar mechanism, we assessed
the activity of Gal4-PCIF1 and Gal4-POZ fusion proteins. In
this assay, transcriptional repressors and repression domains
cloned in-frame with the Gal4 DNA binding domain repress
the high basal activity of the Gal4SV40 luciferase reporter
[20]. Surprisingly, basal reporter activity was not inhibited by
Gal4-PCIF1 or Gal4-POZ (Fig. 5A), although the established
repressive POZ domains from PLZF and BCL6 did inhibit in
this assay. Further, HDAC inhibitors (trichostatin A, sodium
butyrate and nicotinamide) had no eﬀect on the ability of
PCIF1 to inhibit PDX-1 transactivation (Fig. 5B). We exam-
ined whether PCIF1 interacts with HDAC3 and co-repressor
SMRT in MIN6 cells (Fig. 5C). Although we detected the
interaction between HDAC3 and SMRT, we observed no
interaction between PCIF1 and either HDAC3 or SMRT. Sim-
ilarly we did not detect interaction between PCIF1 and
HDAC2 (not shown). Altogether, these data strongly indicate
that the PCIF1 POZ domain is not an autonomous repression
domain and that inhibition of PDX-1 transactivation does not
involve the recruitment of HDACs.
3.7. The PCIF1 C-terminus directs its nuclear localization
HeLa cells were transfected with wild-type and mutant
PCIF1 and expression was determined by immunoﬂuorescence
detection of the Flag epitope (Fig. 6). Consistent with a previ-
ous report [21], the TRAF domain directs PCIF1 localization
to nuclear speckles, as deletion of the TRAF domain in the PC
mutant led to a diﬀuse nuclear localization. Of note, deletionof the C-terminus resulted in cytoplasmic expression, indicat-
ing that the C-terminus mediates nuclear localization of
PCIF1.
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Fig. 5. The PCIF1 POZ domain does not mediate transcriptional
repression. (A) Gal4-PCIF1 and Gal4-POZ domain fusion proteins do
not repress basal Gal4 transactivation in HeLa cells co-transfected
with a Gal4-SV40 Luciferase reporter. Gal4-PLZF POZ and Gal4-Bcl6
POZ both repress basal Gal4 transactivation. *P < 0.001 compared
with empty vector Gal4. (B) The HDAC inhibitors trichostatin A
(300 nM), sodium butyrate (5 mM) and nicotinamide (5 mM) do not
relieve the inhibition of Gal4-PDX1 transactivation caused by PCIF1,
PC or DC. (C) PCIF1 does not interact with SMRT or HDAC3. Left
panel, HeLa cell lysates were immunoprecipitated with non-immune
IgG or HDAC3 antibody. Western blot analysis for HDAC3 and
PCIF1 was performed. Right panel, HeLa cell lysates were immuno-
precipitated with non-immune IgG or SMRT antiserum. Western blot
analysis was performed for SMRT, HDAC3 and PCIF1. The low level
of endogenous SMRT expression precluded detection in the input
sample. Lanes 1 and 5, immune precipitation; lanes 2 and 4, non-
immune control precipitation; lanes 3 and 6, 1% input lysate.
Fig. 6. Conserved PCIF1 TRAF and C terminal domains mediate
proper nuclear localization of PCIF1. Full-length PCIF1 and PCIF1
deletion mutants PC and DC (see Fig. 4A) were transfected into HeLa
cells and visualized by immunoﬂuorescence for the Flag epitope.
Images with (middle panel) and without (left panel) DAPI nuclear
counterstain are shown. DAPI only counterstain is shown in the right
panel.
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PCIF1 is a novel regulatory molecule that interacts with the
homeodomain transcription factor PDX-1. Here, we determine
the critical motifs in both PDX-1 and PCIF1 that are required
for this interaction. Within the PDX-1 C-terminus we demon-
strate an evolutionarily conserved region that mediates both
physical and functional interaction with PCIF1. A recently re-
ported human diabetes causing mutation, E224K [3], located
within this conserved motif disrupts the functional interactionwith PCIF1, suggesting that interaction between PDX-1 and
PCIF1 is required for normal glucose homeostasis. Other
PDX-1 C-terminal variants associated with human diabetes
are located outside the conserved motif and are not impaired
in the functional interaction with PCIF1 in over-expression
reporter assays (Liu and Stoﬀers, unpublished observations).
These mutations may impair PDX-1 function via a PCIF1
independent mechanism; however the observation from this
study that the POZ domain interacts with residues in the
PDX-1 C-terminus outside the conserved motif suggests that
these mutations could also modify the interaction with PCIF1.
The requirement for the POZ domain suggested recruitment
of a repressor complex as a potential molecular mechanism.
The most-well characterized POZ domain transcription factors
recruit repressor complexes through direct interactions with
co-repressors and HDACs [18,19]. However, we found no evi-
dence for PCIF1 POZ domain as a repression domain, nor
could we demonstrate any eﬀect of multiple HDAC inhibitors
or direct interactions with the co-repressor SMRT and
HDACs 2 and 3. These results support a distinct molecular
mechanism for the inhibition of PDX-1 by PCIF1 that does
not involve the classical paradigm of transcriptional repres-
sion.
We identify roles for the TRAF and C-terminal domains in
the subcellular targeting of PCIF1. Consistent with a previous
report, the TRAF domain is required for proper sub-nuclear
localization to nuclear speckles [21], dynamic subnuclear
organelles that may regulate pools of factors required for tran-
scription and splicing and are often observed near sites of ac-
tive transcription (reviewed in [22]). Previously, we observed
that PDX-1 redirected PCIF1 from nuclear speckles to a
6706 A. Liu et al. / FEBS Letters 580 (2006) 6701–6706diﬀuse nuclear distribution [12]. Taken together with the direct
interaction of PDX-1 with the TRAF domain, the results sug-
gest that PDX-1 redirects PCIF1 localization within the nu-
cleus by masking a motif within the TRAF domain required
for localization to speckles. The PCIF1 C-terminus is also re-
quired for nuclear localization. The mechanism for nuclear im-
port is generally unknown for nuclear POZ domain proteins.
Recently, a conserved basic motif mediating nuclear localiza-
tion that did not conform to consensus nuclear import signals
was identiﬁed for the nuclear POZ domain protein Kaiso [23].
Interestingly, this motif bears high homology to a motif in the
C-terminus of PCIF1. Future experiments will determine
whether nuclear import of PCIF1 is mediated by this con-
served motif.
Current research on PDX-1 is unequivocal with regard to its
pivotal position in the transcriptional hierarchy regulating
both early and late pancreatic islet development, critically
underscored by the identiﬁcation of PDX-1 as a human diabe-
tes gene (MODY4); yet many important mechanistic questions
remain unanswered. The identiﬁcation of critical domains
mediating the interaction of PDX-1 and PCIF1 may have po-
tential application to therapeutic b-cell replacement strategies
in type 1 and type 2 diabetes, as PDX-1 is explored as a target
for induction of b-cell neogenesis, transdiﬀerentiation of non-
b-cell types into insulin producing cells, and gene therapy ap-
proaches to modify embryonic and other stem cells for trans-
plantation.
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